Nutrient-Stimulated Hormone Therapy Outcomes in Bariatric Surgery Patients
A retrospective study of 1638 adults examined nutrient-stimulated hormone therapy impacts on weight loss by surgery type and diabetes status. Findings indicate Roux-en-Y gastric bypass patients achieved greater total wei
This research investigates the utilization and clinical outcomes of nutrient-stimulated hormone (NuSH) therapies among adults undergoing bariatric surgery. Understanding these therapeutic effects is relevant for metabolic researchers studying post-surgical metabolic regulation and long-term weight management strategies in clinical settings.
The study employed a retrospective design, analyzing data from 1638 adults who underwent bariatric procedures at a single academic medical center between 2015 and 2022. Researchers utilized electronic health records to extract baseline demographics, NuSH therapy prescriptions, and longitudinal follow-up weight measurements. Statistical analysis involved linear mixed models to calculate percent total weight loss over time.
Key findings demonstrate that patients undergoing Roux-en-Y gastric bypass achieved greater percent total weight loss compared to those who underwent sleeve gastrectomy. Additionally, individuals without pre-existing diabetes exhibited higher weight loss outcomes than those with diabetes. At 72 months post-surgery, adjusted average percent total weight loss was highest in patients receiving NuSH prescriptions both before and after surgery (22.7%, 95% CI: 17.9–27.5). Those with prescriptions only after surgery showed 19.9% weight loss, while those without prescriptions demonstrated 19.6% weight loss.
The greatest percent total weight loss was observed in patients who received NuSH prescriptions within six months following surgery. Individuals undergoing Roux-en-Y gastric bypass without diabetes achieved the highest outcomes overall. Receiving a NuSH prescription both before and after surgery, combined with early initiation of therapy, were associated with the greatest percent total weight loss.
These results suggest that timing and consistency of hormone therapy may influence metabolic outcomes in bariatric patients. However, this study was conducted at a single academic medical center, which may limit generalizability to other clinical settings. The retrospective nature of the design precludes establishing causal relationships between NuSH therapy and weight loss outcomes. These findings should be interpreted within the context of research-use only applications and do not constitute medical advice or product recommendations.